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Abstract: Ergothioneine is a sulfur-containing histidine derivative 
that emerges from microbial biosynthesis and enters the human 
body via intestinal uptake and regulated distribution into specific 
tissues. While the proteins involved in biosynthesis and uptake are 
well characterized, less is known about the degradative pathways of 
ergothioneine. In this report we describe the crystal structure of the 
active form of ergothionase from the oral pathogen Treponema 
denticola in complex with the substrate analog desmethyl-
ergothioneine sulfonic acid. This enzyme catalyzes 1,2-elimination of 
trimethylamine from ergothioneine and its oxidation product 
ergothioneine sulfonic acid using a unique mode of substrate 
activation combined with acid/base catalysis. This structural and 
mechanistic investigation revealed four essential catalytic residues 
that are strictly conserved in homologous proteins from common 
gastrointestinal bacteria and numerous pathogenic bacteria, 
suggesting that bacterial activity may play an important role in 
determining the availability of ergothioneine in healthy and diseased 
human tissue.  
Ergothioneine (1, Figure 1) is a ubiquitous natural product that is 
increasingly recognized as an important micronutrient for 
humans. A growing body of research implicates 1 as a 
protectant against ailments such as inflammatory, 
cardiovascular or infectious diseases, cancer and 
neurodegeneration. [1] In spite of these intriguing leads, the 
molecular mechanisms by which 1 unfolds its protective 
activities are unknown. Because animals do not produce 1 
themselves, the tissue concentration of this compound critically 
depends on the dietary supply, the absorption in the intestine, 
systemic distribution and the rates at which this micronutrient is 
lost by secretion or by degradation. Intestinal absorption occurs 
via the highly selective ergothioneine transporter ETT.[2] 
Distribution of 1 into specific cell-types or tissues such as red 
blood cells, bone marrow, liver, or kidney is governed by 
transcriptional regulation of the ETT-coding gene SLC22A4.[3] 
Up-regulation of this gene was also observed as a response to 
tissue damage,[1c, 4] suggesting that the active control of 
ergothioneine levels may be part of an adaptive cytoprotective 
system.[1b] This specific and possibly dynamic system for uptake 
and distribution provides strong evidence that 1 plays an integral 
and dose-dependent role in the human body, and might be 
considered as a vitamin.[5]  
 
 
Figure 1. Ergothioneine metabolism: a, b) Biosynthesis of ergothioneine (1); c, 
d) Oxidative degradation of 1; e) Methylation of 1 by an unknown methyl 
donor; f, g: ETL-catalyzed elimination of trimethylamine from 1 and 3; h) 
Desulfurization of 5 and 10 by unknown enzymes could form urocanate (6), 
which is degraded to the citric acid cycle component a-ketoglutarate (7). i) 
Histidine ammonia lyase (HAL)-catalyzed degradation of histidine.  
Ergothioneine enters the food chain by fungal and bacterial 
biosynthesis, followed by absorption or ingestion by plants and 
animals.[1a] Identification of ergothioneine biosynthetic enzymes 
revealed that most fungi and many bacteria, including most 
actinobacteria and cyanobacteria produce 1 from histidine, via 
trimethylation of the a-amino group to form N-a-trimethyl 
histidine (2), followed by attachment of a sulfur atom to the 
imidazole side chain (Figure 1).[6] Mechanistic and structural 
characterization of the key enzymes along these pathways 
made it possible to identify ergothioneine biosynthetic genes 
from genomic data with considerable certainty.[7] 
 
The degradative pathways of 1 are more complex and less well 
understood. Reactive oxygen species can oxidize 1 to the 
corresponding sulfonic acid (3), or cause oxidative 
desulfurization (Figure 1).[8] Another pathway is methylation by 
an unknown methyl donor to form S-methyl ergothioneine (4). 
So far, there is no evidence that these reactions are catalyzed 
by specific enzymes and hence these pathways have no direct 
genetic footprint. On the other hand, the discovery of 
ergothioneine degrading activity in Enterobacteria,[9] and the 
identification of a specific enzyme from Burkholderia sp. that 
cleaves 1 into trimethylamine and thiourocanic acid (5) 
(Ergothioneine Trimethylammonia Lyase, BuETL) provided early  
evidence that degradation of 1 is also a genetically traceable  
process.[10]  
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Figure 2. TdETL homotetramer (left) with a close-up view into active site A in complex with desmethyl-ergothioneine sulfonic acid (8, right). Active site residues 
and 8 are shown in stick representation and color coded according to monomer (A: green, B: orange, C: red). The 2m|F0| - D|Fc| omit map for 8 is contured at s-
level = 1.0. 
   
This realization raised the intriguing possibility that the 
concentration of 1 in food products, in the gastrointestinal 
tract and in specific tissues may also depend on bacterial 
activity. To enable identification of ETL-coding genes in 
bacteria we examined the crystal structure and catalytic 
mechanism of ETL from the pathogenic oral spirochete 
Treponema denticola. Based on these results we identified a 
set of active site residues that are essential for specific 
ergothionase activity. These residues are strictly conserved 
many homologous proteins encoded predominantly in 
firmicutes and proteobacteria, and also in several pathogenic 
bacteria from other phyla.  
 
Crystal structure of ergothionase. ETL from T. denticola 
(TdETL, acession number: WP_010693216) was identified 
based on its sequence similarity to BuETL (34 % sequence 
identity).[10] The codon-optimized gene for TdETL was 
expressed from a modified pET19(+) vector in Escherichia 
coli and purified following standard protocols (see supporting 
information). Crystals of TdETL in native form and in complex 
with 8 were grown in tris-buffered solutions (pH 7.4) 
containing PEG4000, PEG200 and CaCl2. One diffraction 
data set with a resolution of 2.1 Å was used to solve the 
structure of native TdETL by molecular replacement (Table 
S1). The structure of the TdETL:8 complex was solved to a 
resolution of 2.6 Å using the native structure as a template.  
The electron densities of the two TdETL structures reveal a 
continuous polypeptide chain from Asp2 to Ile498 (Figure 2 
and S6). The overall structure of TdETL is strikingly similar to 
that of histidine ammonia lyase (HAL, PDB: 1B8F, Figure S7) 
from Pseudomonas putida.[11] The backbones of the two 
proteins superimpose with an RMSD of 1.58 Å over 393 
residues, despite sharing only 26 % sequence identity. Four 
largely a-helical monomers form a tetramer with D2 symmetry 
hosting four identical active sites that are lined by residues 
from three different monomers (Figure 2). 
 
The crystal of the TdETL:8 complex contained residual 
electron density in the active site that allowed unambiguous 
placement of the ligand (Figure 2). Superposition of the native 
and the liganded structures shows no indication of 
conformational change upon ligand binding, suggesting that 
the enzyme provides a highly preorganized substrate-binding 
pocket (Figure S6 and S8). The two N-a-methyl groups of 8 
pack against the aromatic plane of Phe327 and make close 
contacts with the backbone carbonyl of Glu143 (2.7 Å & 2.8 
Å). Surprisingly, Glu143 adopts a conformation that points the 
sidechain away from the dimethyl amino moiety, indicating 
that the amino group of the substrate may not be protonated 
in the complex and therefore does not require stabilization by 
a complementary charge. The carboxylate of 8 approaches 
the side chains of Arg281 (3.7 Å) and Asn311 (3.5 Å), but the 
rather long distances suggest that electrostatic interactions 
may be more important than hydrogen-bonding. The aromatic 
plane of the imidazole ring is squeezed between the 
hydrophobic side chains of Val60 and Ile146. The two 
imidazole N-H groups of 8 interact with the hydrogen bond 
acceptors Glu412 (Np, 2.8 Å) and His84 (Nt, 3.2 Å). His84 
also hydrogen bonds with Ser83 which in turn hydrogen 
bonds with the backbone carbonyl of Asn79 (Figure 2). This 
hydrogen bonded triad stabilizes His84 as a hydrogen-bond 
acceptor with respect to ligand 8. The sulfonic acid moiety 
hydrogen bonds with the side chains of Thr381 and Lys384. 
Finally, the phenol function of Tyr54 hovers right above the b-
methylene group of 8, well-positioned for abstraction of the 
pro-S proton from the substrate. Structurally equivalent 
tyrosine residues have been identified as the catalytic base in 
HAL and related ammonia lyases and mutases.[11-12]  A model 
of TdETL in complex with 1 shows that the native substrate  
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Table 1.[a] 
entry enzyme substrate kcat 
[s-1] 
kcat/ KM 
[s-1M-1] 
AA TdETLwt 1 64 ± 3 1.4 x 106 
BB TdETLY54F 1 0.02 ± 0.001 6.5 x 102 
EC TdETLK384M 1 0.02 ± 0.01 5.0 x 102 
DD TdETLE412Q 1 0.05 ± 0.01 2.4 x 102 
CE TdETLK64M 1 0.11 ± 0.01 1.1 x 105 
FF TdETLwt 3 17 ± 1 1.1 x 105 
GG TdETLY54F 3 0.003 ± 0.001 1.7 x 101 
IH TdETLK384M 3 0.005 ± 0.001 2.8 x 100 
HI TdETLE412Q 3 0.002 ± 0.001 4.6 x 102 
JJ TdETLwt 2 0.04 ± 0.002[b] - 
K TdETLwt 4 0.001[b] - 
L TdETLK384M 2 0.2 ± 0.01[b] - 
M TdETLK384M 4 0.09 ± 0.001[b] - 
N TdETLwt 8 0.0022[b] - 
O TdETLwt 9 0.012[b] - 
P TdETLwt histidine 0.0001[b] - 
[a] Displayed values represent averages from three independent 
measurements. The corresponding Michaelis-Menten plots are shown in 
the supporting information. Initial rates determined at different [S]t=0 were 
fitted with v = kcat [S]/(KM + [S]). [b] These parameters correspond to kobs = 
(dP/dt)obs/[S]t=0, determined at a [S]t=0 = 2 mM.  
 
can make the same contacts with the active site (Figure S9, 
Figure 3). In particular, the enzyme appears to accommodate 
the difference between the imidazole sulfonic acid side chain 
of 8 and the 2-mercaptoimidazole of 1 with minimal 
conformational change. 
 
Kinetic characterization. To examine how this active site 
catalyzes the elimination of trimethylamine from 1 we 
measured the activity of TdETL using a UV-Vis based assay 
that monitors production of 5 in a HEPES-buffered solution at 
pH 7.5 and 23°C (Figure S11). Under these conditions 
TdETL-catalyzed production of 5 is characterized by a kcat of 
64 s-1 and a catalytic efficiency (kcat/ KM) of 1.4 x 106 M-1s-1 
(Table 1, entry A). The pH-dependence of kcat follows a bell-
shaped curve with a maximum near 7.5 (pKa1 = 6.6 ± 0.1, 
pKa2 = 8.7 ± 0.1, Figure S12 and S13). This behavior is 
diagnostic for a mechanism that depends on general acid and 
base catalysis. Measuring TdETL activity with deuterated 1 
revealed a primary substrate kinetic isotope effect (KIE) of 1.8 
± 0.2 on kcat, suggesting that base-catalyzed C-H bond 
cleavage is partially rate limiting. In contrast, kcat/KM is much 
less affected by substrate deuteration (KIE = 1.2 ± 0.1), 
suggesting that C-H bond cleavage is not rate limiting at low 
substrate concentrations (Figure S14). The most likely 
interpretation of this behavior is that substrate-unbinding is 
slow relative to the forward reaction (C-H cleavage), which 
makes substrate binding essentially irreversible.[13] 
Independent of this interpretation, these results highlight that 
for TdETL the KM is not a measure of substrate affinity (KS = 
koff/kon) but instead is dominated by the ratio between kcat and 
the rate of substrate binding (KM = kcat/kon). 
 
In a next step we probed the effect of three mutations that 
eliminate polar interactions between the enzyme and the 
ligand. Mutation of Tyr54 to Phe, Lys384 to Met, and Glu412  
 
Figure 3. Top: Proposed substrate binding mode and mechanism for 
substrate activation by TdETLwt. Bottom: Charge complementary 
enzyme:ligand complexes that stabilize a positive charge on the imidazole 
ring (green) are more active that complexes with unbalanced charge or a 
neutral imidazole ring (red). Bold letters indicate the corresponding entry in 
table 1  
 
to Gln each reduced kcat and catalytic efficiency by over three 
orders of magnitude (entries B, C and D, Table 1). These 
strong effects demonstrate that the three residues are 
absolutely essential for catalysis. In contrast, mutation of 
Lys64 to Met decreased catalytic efficiency only by 10-fold 
(entry E). In the TdETL:8 complex and the native structure 
Lys64 adopts a conformation that points the side chain 
toward the protein exterior (Figure 2, Figure S6). However, 
the electron density of a second native crystal indicates an 
alternative conformation of Lys64 placing the e-amino 
function of the side chain in proximity to the phenol function of 
Tyr54 (Figure S8). Hence, in this conformation Lys64 could 
suppress the pKa of Tyr54 and therefore activate this residue 
as a catalytic base. Consistently, mutation of Lys64 to Met 
resulted in a TdETL variant with a pH optimum that is 1.5 
units higher than that of wild type (pKa1 = 8.2 ± 0.2, pKa2 = 9.5 
± 0.1, Figure S15 and S16). Comparison of the wild type and 
variant pH-dependence curves showed that this shift is 
predominantly due to an increase of pKa1 (Figure S17). 
 
Substrate specificity profile of TdETL. As a 
complementary approach to study enzyme:substrate 
interactions that are important for ETL-activity, we examined 
the range of accepted substrate analogs. Most interestingly, 3 
is consumed by TdETL with a catalytic efficiency only ten-fold 
lower than measured for 1 (entry F, Table 1). Mutation of 
residues Tyr54, Lys384 and Glu412 caused similar reduction 
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of the catalytic efficiency for 3 (entries G, H, I), corroborating 
the proposition that 1 and 3 make similar interactions with the 
active site (Figure S18). Apparently, the relatively bulky and 
anionic head group is well tolerated by the enzyme. In 
contrast, N-a-trimethylhistidine (2) and S-methyl 
ergothioneine (4) are both poor substrates (entries J and K) 
even though they seem structurally more similar to 1. Also, 
desmethyl ergothioneine (9) and desmethyl ergothioneine 
sulfonic acid (8) are poor substrates (entries N and O) despite 
having identical side chains as 1 and 3. Finally, histidine is 
turned over almost 106-fold slower that the native substrate 1 
(entry P) underscoring the functional difference between 
ergothionases and histidine ammonia lyases.[10]        
 
Mechanisms of substrate activation. The ability of TdETL 
to accept 3 as an alternative substrate while rejecting 2, 4, 8 
and 9 provides important clues as to how the enzyme binds 
and activates its native substrate 1. The structure of TdETL:8 
and the efficient turnover of 3 suggests that the active site is 
well-equipped to solvate the zwitterionic side chain with a 
positive charge on the imidazolium ring and an anionic head 
group (Figure 3F). The native substrate 1 can be drawn as a 
resonance structure with the same zwitterionic charge 
distribution that can also interact with Glu412 and Lys384 to 
form an overall neutral complex (Figure 3A). The positive 
charge on the imidazole ring inevitably renders the adjacent 
b-methylene group more acidic which likely activates the 
substrate for base-catalyzed proton abstraction. This 
activation mechanism seems crucial for catalysis. 
Compounds 2 and 4 cannot attain a zwitterionic state, forcing 
these ligands to bind with a neutral side chain. Hence the b-
methylene group of these substrates remain unactivated 
(Figure 3K and 3J). Consistent with this model, we found that 
the variant TdETLK384M which lacks one positive charge and 
may therefore bind the imidazole rings in protonated form, 
consumes 2 and 4 5- and 90-fold more efficiently than the 
wild type (Figure 3L and 3M). The fact that the Lys384Met 
mutation decreased the catalytic efficiency for 1 and 3 by 
three orders of magnitude underscores the importance of 
charge complementarity between the active site and the 
substrate with a protonated imidazole ring (Figure 3C & 3H).  
 
The observation that 8 and 9 are also poor substrates 
highlights a second contribution to substrate activation. The 
structure of the TdETL:8 complex shows that the dimethyl 
amino group is buried in a relatively non-polar and neutral 
pocket that provides no direct counterion to stabilize the 
cationic charge of a protonated amine. 8 and 9 can 
accommodate by binding with a neutral a-amino group. 
However, neutral dimethyl amine is a poor leaving group. 
Consequently, turnover of 8 and 9 is barely measurable Table 
1). By contrast, binding of the substrates 1 and 3 forces the 
quaternary ammonium group into the same apolar pocket 
which likely increases the leaving group ability of this moiety. 
In summary, the structure and substrate specificity profile of 
TdETL show that this enzyme activates its substrate by a) 
polarization of the side chain and b) destabilization of the 
leaving group. If either of the two activation modes is 
inaccessible, catalysis is three orders of magnitude less 
efficient.      
 
ETL in commensal and pathogenic bacteria. The four 
residues we found essential for catalysis in TdETL are strictly 
conserved in 260 homologous proteins (UniProt database) 
encoded by proteobacteria (163), firmicutes (73), 
synergistetes (16), and miscellaneous species from other 
phyla (Table S3). This group includes  many gastrointestinal 
bacteria such as Blautia spp., Clostridium spp., Paenibacillus 
spp., Peptoniphilus spp., Campylobacter spp., and  
Escherichia spp., indicating that  non-oxidative degradation of 
1 is a common trait in the gut microbiome.[14] Although the 
quantitative aspects of ergothioneine breakdown in the 
gastrointestinal tract have yet to be explored, it seems 
possible that the composition of the gut microbiome may be a 
factor in determining the availability of this vitamin for the host. 
In addition, the ETL product trimethylamine and particularly 
its oxidative degradation product trimethylamine N-oxide 
(TMAO) have been linked to medical problems such as 
nonalcoholic fatty acid liver disease and cardiovascular 
disease.[15] Hence, overconsumption of ergothioneine as a 
food additive may have undesirable side effects.  
 
The presence of ETL homologs in numerous pathogens, such 
as Chlamydia trachomatis, Fusobacterium nucleatum,[16] T. 
denticola,[17] or B. pseudomallei,[18] raise the additional 
possibility that ergothioneine degradation may contribute to 
the virulence and persistence of these bacteria in human 
tissue. For example, T. denticola participates in bacterial 
consortia that are associated with chronic inflammation of the 
periodontal tissues.[19] One factor that contributes to virulence 
of T. denticola is the conversion of glutathione to hydrogen 
sulfide which can affect host tissue as cytotoxin, or can 
dysregulate the host defense systems by activating both pro- 
and anti-inflammatory  mechanisms.[20] ETL activity may allow  
T. denticola  and other oral pathogens to recruit ergothioneine 
as an alternative sulfur source in the progression of 
periodontal disease. 
 
Conclusions. In this report we described the crystal structure 
of ETL from the human pathogen T. denticola in complex with 
the slow substrate analog desmethyl ergothioneine sulfonic 
acid. This structure, combined with the catalytic activities of 
the wild type enzyme and active site variants identified a set 
of polar interactions between the enzyme and its substrate 
that are essential for catalysis. The same active site 
configuration occurs in homologous proteins encoded in 260 
bacterial genomes. This work paves the way to investigate 
the potential impact of bacterial ergothioneine degradation on 
human health. The discovery that many common members of 
the gut microbiome catabolize 1 to the problematic metabolite 
trimethylamine may provide a cautionary corrective to the 
increasing advertisements of this natural product as a food 
additive. On a different note, the structure and mechanistic 
characterization of TdETL opens the door for comparison to 
related enzymes such as HAL or aspartate ammonia-lyase 
that catalyze similar 1,2-elimination reactions but use different 
mechanisms for substrate activation.[11-12, 21]         
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